ethyl (E)-2-(bromomethyl)cinnamate | 60633-90-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: ethyl (E)-2-(bromomethyl)cinnamate
• 英文别名: ethyl (E)-3-<2-(bromomethyl)phenyl>-2-propenoate；(E)-ethyl 2-bromomethylcinnamate；ethyl o-bromomethylcinnamate；ethyl (E)-3-[2’-(bromomethyl)phenyl]acrylate；ethyl (E)-3-[2-(bromomethyl)phenyl]-2-propenoate；trans-o-(Brommethyl)-zimtsaeureethylester；ethyl 2-bromomethylcinnamate；2-Propenoic acid, 3-[2-(bromomethyl)phenyl]-, ethyl ester, (E)-；ethyl (E)-3-[2-(bromomethyl)phenyl]prop-2-enoate
• CAS: 60633-90-1
• 化学式: C₁₂H₁₃BrO₂
• 分子量: 269.138
• InChiKey: QHLPDXFUAWWTON-BQYQJAHWSA-N

物化性质

• 沸点：
  342.9±22.0 °C(Predicted)
• 密度：
  1.370±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl (E)-2-(bromomethyl)cinnamate 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 32.0h， 生成 (+/-)-1,3-dihydrobenzothiophene-1-acetic acid
  参考文献：
  名称：

  Tandem SN2-Michael reactions for the preparation of simple five- and six-membered-ring nitrogen and sulfur heterocycles

  摘要：

  A one-pot tandem S(N)2-Michael addition sequence has been developed for the preparation of five-membered- and six-membered-ring nitrogen and sulfur heterocycles from 6- or 7-halo-2-alkenoate esters. Nitrogen-containing rings are prepared by reaction of the omega-halo-2-alkenoate ester with a primary amine in the presence of triethylamine. The sulfur analogues are generated by thiourea displacement of the halide followed by base hydrolysis of the isothiouronium salt. Yields are routinely in the 60-80% range. Experiments are described which elucidate the chronology of the reaction sequences. Ring size and steric hindrance to the initial substitution reaction appear to be the only limitations of the procedure.

  DOI：

  10.1021/jo00032a025
• 作为产物：
  描述：

  反式-肉桂酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 正己烷 、 乙酸乙酯 为溶剂， 生成 ethyl (E)-2-(bromomethyl)cinnamate
  参考文献：
  名称：

  Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment

  摘要：

  公式I的化合物，以及其药学上可接受的盐、水合物和酯被揭示出来。这些化合物可用于治疗或预防前列腺素介导的疾病。还包括含有这些化合物的药物组合物和治疗方法。

  公开号：

  US06242493B1

文献信息

• Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives
  作者：Kinji Iizuka、Kenji Akahane、Denichi Momose、Masayuki Nakazawa、Tadao Tanouchi、Masanori Kawamura、Isao Ohyama、Ikuo Kajiwara、Yohichi Iguchi

  DOI：10.1021/jm00142a005

  日期：1981.10

  structure--activity relationships of imidazole derivatives as inhibitors of thromboxane (TX) synthetase were investigated. Introduction of various substituents (e.g., one or two methyl groups, a halogen atom, a methylidene group, unsaturated bonds, or a phenylene group) into the alpha position or other positions in the carboxy-bearing side chain of 1-(7-carboxyheptyl)imidazole (15) was found to increase the

  研究了咪唑衍生物作为血栓烷（TX）合成酶抑制剂的构效关系。将各种取代基（例如一个或两个甲基，卤原子，亚甲基，不饱和键或亚苯基）引入1-（7-羧基庚基）的含羧基侧链的α位或其他位置发现咪唑（15）增强了抑制效力。带有亚苯基的侧链的长度对于在8.5-9.0 A范围内对TX合成酶的抑制效力而言是最佳的。在测试的咪唑衍生物中，1-（7-羧基-7-甲基-2-辛基）咪唑（47），4- [3-（1-咪唑基）-丙基]苯甲酸（50），
• Interphenylene 11,12-secoprostaglandins
  申请人：Merck & Co., Inc.

  公开号：US04140861A1

  公开（公告）日：1979-02-20

  Novel interphenylene derivatives of 11,12-secoprostaglandins are prepared by the stepwise alkylation of the ethyl ester or the t-butyl ester of acetoacetic acid. One such method involves treatment of the t-butyl ester of acetoacetic acid with a strong base to form the anion followed by treatment with ethyl p-(3-bromopropyl)benzoate to produce ethyl 4-(4-tert-butoxycarbonyl-5-oxo-hexyl)benzoate, subsequently reacting the anion of the thus-formed benzoate with 1-chloro-4-acetoxynonane to produce ethyl 4-(4-acetyl-4-tert-butoxycarbonyl-8-acetoxytridecyl)benzoate followed by decarboxylation and alkaline hydrolysis to produce the desired product 4-(4-acetyl-8-hydroxytridecyl)benzoic acid which is useful as a pharmaceutical in the treatment of patients with renal failure and in the prevention of transplant rejection.

  11,12-secoprostaglandins的新型间苯二酚衍生物是通过乙酸乙酯或乙酸叔丁酯的逐步烷基化制备的。其中一种方法涉及将乙酸叔丁酯用强碱处理以形成阴离子，随后用乙基对-(3-溴丙基)苯甲酸酯处理以产生乙基 4-(4-叔丁氧羰基-5-氧代己基)苯甲酸酯，随后将所形成苯甲酸酯的阴离子与1-氯-4-乙酰氧基壬烷反应，产生乙基 4-(4-乙酰基-4-叔丁氧羰基-8-乙酰氧基十三烷基)苯甲酸酯，然后进行脱羧和碱性水解以产生所需的产物4-(4-乙酰基-8-羟基十三烷基)苯甲酸，该产物可用作药物治疗肾衰竭患者和预防移植排斥的药物。
• Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors
  作者：Antonello Mai、Silvio Massa、Dante Rotili、Silvia Simeoni、Rino Ragno、Giorgia Botta、Angela Nebbioso、Marco Miceli、Lucia Altucci、Gerald Brosch

  DOI：10.1021/jm0605536

  日期：2006.10.1

  A novel series of compounds containing a uracil moiety as the connection unit between a phenyl/phenylalkyl portion and a N-hydroxy-polymethylenealkanamide or -methylenecinnamylamide group (uracil-based hydroxamic acids, UBHAs) was tested against maize histone deacetylases (HDACs) and mouse HDAC1. Compounds with a phenyl/benzyl ring at the uracil-C6 position and bearing 4-5 carbon units as well as a

  测试了一系列新的化合物，其中包含尿嘧啶部分作为苯基/苯基烷基部分与N-羟基-聚亚甲基铝酰胺或-亚甲基肉桂酰胺基之间的连接单元（基于尿嘧啶的异羟肟酸，UBHA）对玉米组蛋白脱乙酰基酶（HDACs）和小鼠的抑制作用HDAC1。最有效的抑制剂是在尿嘧啶-C6位置具有苯基/苄基环且带有4-5个碳单元以及间-或对-亚甲基肉桂基部分作为间隔基的化合物。在基于细胞的人类HDAC1和HDAC4分析中，测试的两个UBHA抑制了HDAC1，但没有抑制HDAC4的免疫沉淀活性。在人白血病U937细胞中进行测试时，一些UBHA会导致细胞周期的G1期停滞。此外，1j显示出高抗增殖和剂量依赖性的粒细胞分化特性。
• Tandem annulation strategy for the convergent synthesis of benzonaphthopyranones: total synthesis of chartarin and O-methylhayumicinone
  作者：Sutapa Ray、Asit Patra、Dipakranjan Mal

  DOI：10.1016/j.tet.2008.01.039

  日期：2008.3

  A Hauser-initiated tandem annulation has been developed for the rapid regiospecific synthesis of benzonaphthopyranones via formation of two rings in one-pot operation. This strategy has been generalized with benzonaphthopyranones 26, 29, 32, and 35. It has also been employed in a short synthesis of chartarin (3) and O-methylhayumicinone (67).

  豪瑟（Hauser）引发的串联环已开发出来，用于通过一锅操作形成两个环来快速区域特异性合成苯并萘并吡喃酮。这种策略已经被推广以benzonaphthopyranones 26，29，32，和35。它也已被用于沙丁鱼酯（3）和O-甲基干草umi酮（67）的短合成中。
• Prostaglandin receptor ligands
  申请人：Merck Frosst Canada & Co.

  公开号：US06211197B1

  公开（公告）日：2001-04-03

  Compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof are disclosed. The compounds are represented by formula II: Ar1—W—Ar2—X—Q  II The compounds of the invention are structurally different from NSAIDs and opiates, and are antagonists of the pain and inflammatory effects of E-type prostaglandins.

  本发明揭示了用于治疗前列腺素介导疾病的化合物和方法，以及某些制药组合物。这些化合物由式II表示：Ar1—W—Ar2—X—Q。该发明的化合物在结构上与非甾体类抗炎药和阿片类药物不同，是E型前列腺素的疼痛和炎症作用的拮抗剂。